Shirley Cohen-Mekelburg

Shirley Cohen-Mekelburg

Auto-generated profile, based on publicly available information

Shirley Cohen-Mekelburg

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine , Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
SCShirley Cohen
Shirley Cohen
ASAditi Saxena
Aditi Saxena
AWAkbar K. Md Waljee
Akbar K. Md Waljee
CPCyrus Piraka
Cyrus Piraka
JPJulianne Purdy
Julianne Purdy
ASAmit Singal
Amit Singal
Background: Despite being found with increasing frequency on esophageal biopsies, the clinical significance of lymphocytic esophagitis (LE) remains poorly understood. Goals: The primary aim of our study was to characterize the clinical presentation and natural history of LE among adult patients. Study: We retrospectively reviewed records for all 81 adult patients at the University of Michigan Medical Center who had a histopathologic diagnosis of LE between January 1998 and November 2009. Patient demographics, clinical history, laboratory data, and imaging results from the time of diagnosis were obtained through review of computerized medical records. A telephone survey was conducted to collect natural history data. Results: The number of LE diagnoses increased over time, with 81.5% (n=66) of patients being diagnosed in the last 3 years. The most frequent symptoms at the time of presentation were dysphagia (n=54), chest/abdominal pain (n=36), and heartburn (n=38). The majority (58.6%) of patients reported improvement in their initial gastrointestinal symptoms—most commonly associated with initiation of a proton pump inhibitor. Upon follow-up, most patients reported a good quality of life and satisfaction with their current health status. Conclusions: LE is a new clinical entity with an increasing incidence. LE seems to have a benign natural history, with most patients reporting an improvement in symptoms and satisfaction with their health-related quality of life. Prospective studies are needed to better characterize the natural history and potential treatments for this clinical entity.

1 June 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
VJVinita Jacob
Vinita Jacob
CCCarl Crawford
Carl Crawford
SCShirley Cohen-Mekelburg
Shirley Cohen-Mekelburg
MVMonica Viladomiu
Monica Viladomiu
GPGregory G. Putzel
Gregory G. Putzel
SOSarah O'Neil
Sarah O'Neil
Background. Recent trials suggest fecal microbiota transplantation (FMT) with repeated enemas and high-diversity FMT donors is a promising treatment to induce r

23 August 2024 in Gut
Verified
Journal Article
Closed access
PDF file
MEMaria Manuela Estevinho
Maria Manuela Estevinho
VMVishal Midya
Vishal Midya
SCShirley Cohen-Mekelburg
Shirley Cohen-Mekelburg
KAKristine Højgaard Allin
Kristine Højgaard Allin
Mathurin FumeryMathurin Fumery
Mathurin Fumery
MAManasi Agrawal
Manasi Agrawal
Epidemiological and translational data increasingly implicate environmental pollutants in inflammatory bowel disease (IBD). Indeed, the global incidence of IBD has been rising, particularly in developing countries, in parallel with the increased use of chemicals and synthetic materials in daily life and escalating pollution levels. Recent nationwide and ecological studies have reported associations between agricultural pesticides and IBD, particularly Crohn’s disease. Exposure to other chemical categories has also been linked with an increased risk of IBD. To synthesise available data and identify knowledge gaps, we conducted a systematic review of human studies that reported on the impact of environmental pollutants on IBD risk and outcomes. Furthermore, we summarised in vitro data and animal studies investigating mechanisms underlying these associations. The 32 included human studies corroborate that heavy and transition metals, except zinc, air pollutants, per- and polyfluorinated substances, and pesticides are associated with an increased risk of IBD, with exposure to air pollutants being associated with disease-related adverse outcomes as well. The narrative review of preclinical studies suggests several overlapping mechanisms underlying these associations, including increased intestinal permeability, systemic inflammation and dysbiosis. A consolidated understanding of the impact of environmental exposures on IBD risk and outcomes is key to the identification of potentially modifiable risk factors and to inform strategies towards prediction, prevention and mitigation of IBD.

26 January 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JBJeffrey A. Berinstein
Jeffrey A. Berinstein
TKTaylor Karl
Taylor Karl
APAnish Patel
Anish Patel
MDMichael Dolinger
Michael Dolinger
TBTerrence A. Barrett
Terrence A. Barrett
PHPeter D.R. Higgins
Peter D.R. Higgins
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

7 March 2023 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
JSJessica L. Sheehan
Jessica L. Sheehan
LGLaVana Greene-Higgs
LaVana Greene-Higgs
LSLinnea Swanson
Linnea Swanson
PHPeter D.R. Higgins
Peter D.R. Higgins
SKSarah L. Krein
Sarah L. Krein
SCShirley Cohen-Mekelburg
Shirley Cohen-Mekelburg
INTRODUCTION: Self-efficacy, i.e., the confidence in one's capacity to perform a behavior, is crucial to the development of inflammatory bowel disease (IBD) self-management skills. We aimed to measure IBD self-efficacy and the relationship between self-efficacy and the patient-reported impact of IBD on daily life. METHODS: We surveyed patients with IBD from a single academic center using the IBD Self-Efficacy Scale (IBD-SES) and patient-reported outcome (PRO) measures. The IBD-SES assesses 4 IBD domains: patients' confidence in managing stress and emotions, symptoms and disease, medical care, and remission. IBD PROs evaluate daily life impact, coping strategies, emotional impact, and systemic symptoms. We examined the association between IBD-SES domains with the lowest scores and IBD daily life impact. RESULTS: A total of 160 patients completed the survey. Domain scores on the IBD-SES were lowest for managing stress and emotions (mean 6.76, SD 1.86) and symptoms and disease (mean 6.71, SD 2.12) on a 1–10 scale. Controlling for age, sex, IBD type, disease activity, moderate-to-severe disease, depression and anxiety, a higher confidence in managing stress and emotions (β −0.12, 95% confidence interval −0.20 to −0.05, P = 0.001), and managing symptoms and disease (β −0.28, 95% confidence interval −0.35 to −0.20, P < 0.001) were each associated with lower IBD daily life impact. DISCUSSION: Patients with IBD report low confidence in managing stress and emotion and managing symptoms and disease. Higher self-efficacy in these domains was associated with lower IBD daily life impact. Self-management tools that promote self-efficacy in managing these domains have the potential to reduce IBD's daily life impact.

12 August 2022 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SCShirley Cohen-Mekelburg
Shirley Cohen-Mekelburg
TVTony Van
Tony Van
BWBeth Wallace
Beth Wallace
JBJeff Berinstein
Jeff Berinstein
XYXianshi Yu
Xianshi Yu
AWAkbar K. Waljee
Akbar K. Waljee
INTRODUCTION: Studies suggest that nonsteroidal anti-inflammatory drugs (NSAID) may contribute to inflammatory bowel disease (IBD) exacerbations. We examined whether variation in the likelihood of IBD exacerbations is attributable to NSAID. METHODS: In a cohort of patients with IBD (2004–2015), we used 3 analytic methods to examine the likelihood of an exacerbation after an NSAID exposure. First, we matched patients by propensity for NSAID use and examined the association between NSAID exposure and IBD exacerbation using an adjusted Cox proportional hazards model. To assess for residual confounding, we estimated a previous event rate ratio and used a self-controlled case series analysis to further explore the relationship between NSAID and IBD exacerbations. RESULTS: We identified 15,705 (44.8%) and 19,326 (55.2%) IBD patients with and without an NSAID exposure, respectively. Findings from the Cox proportional hazards model suggested an association between NSAID and IBD exacerbation (hazard ratio 1.24; 95% confidence interval 1.16–1.33). However, the likelihood of an IBD exacerbation in the NSAID-exposed arm preceding NSAID exposure was similar (hazard ratio 1.30; 95% confidence interval 1.21–1.39). A self-controlled case series analysis of 3,968 patients who had both an NSAID exposure and IBD exacerbation demonstrated similar exacerbation rates in the 1 year preceding exposure, 2–6 weeks postexposure, and 6 weeks to 6 months postexposure, but a higher incidence in 0–2 weeks postexposure, suggesting potential confounding by reverse causality. DISCUSSION: While we see an association between NSAID and IBD exacerbations using traditional methods, further analysis suggests this may be secondary to residual bias. These findings may reassure patients and clinicians considering NSAID as a nonopioid pain management option.